Combination Immunotherapy ICOS Agonist Tumor Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using T cell inhibitory receptor blockade, such as CTLA-4 and PD-1, have limitations in efficacy and understanding of ICOS signaling's role in tumor responses, necessitating the exploration of combined therapies to enhance anti-tumor effects.
Innovation Solution
Concurrent administration of an ICOS agonist with T cell inhibitory receptor blockade, utilizing ICOS antibodies and ICOS-Ligand expressing vaccines to stimulate ICOS signaling, thereby enhancing T cell activation and anti-tumor responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell inhibitory receptor blockade (CTLA-4 or PD-1) is used alone, then some anti-tumor effect is achieved, but the efficacy is limited and insufficient for optimal treatment
Solution Approach 1:
The patent combines T cell inhibitory receptor blockade (anti-CTLA-4 or anti-PD-1) with ICOS agonist stimulation in a single combination therapy regimen. This merging of two distinct mechanisms—blocking inhibition and activating costimulation—produces synergistic anti-tumor effects that exceed the sum of individual therapies, directly resolving the limitation of single-agent efficacy while maintaining a manageable therapeutic complexity
2Reliability
If ICOS agonist is added to T cell inhibitory receptor blockade, then anti-tumor efficacy is significantly enhanced, but the therapy complexity increases
Solution Approach 1:
The patent merges T cell inhibitory receptor blockade with ICOS agonist stimulation into a unified combination therapy. The synergistic interaction between these two mechanisms produces enhanced anti-tumor efficacy while the protocols provide clear guidance on administration, making the increased complexity manageable and justified by the substantial therapeutic benefit
Solution Approach 2:
The patent introduces ICOS agonist as an intermediary that bridges the gap between T cell recognition and full activation. By stimulating ICOS on T cells that have been primed through inhibitory receptor blockade, the agonist acts as a mediator that translates partial activation into robust anti-tumor responses, thereby enhancing efficacy without requiring complete redesign of the therapeutic approach
Data Source
AI summary
Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.